SKIM names Maura Coracini as Managing Director, Latin America
SKIM has named Maura Coracini as Managing Director, Latin America. Based in the São Paulo area.
The recent shift towards consumerism and patient empowerment is driving companies to reevaluate the role and design of patient support programs. Historically, pharmaceutical manufacturers implemented support programs largely as a way to address patient non-adherence. These programs were often single-based solutions designed to meet mass market needs. Next generation patient support programs will go beyond simple adherence to address holistic disease management through patient-centric service offerings.
These next-generation “beyond the pill” patient programs are still new, and many of the concepts have yet to be widely embraced. However, some pharmaceutical companies have already begun re-evaluating their current set of offerings with the goal of enhancing patient engagement, retaining brand loyalty, and thwarting the switch to biosimilars or other competitive branded products.
In this article published exclusively in WARC, Bill Salokar – our VP Client Solutions – discussed how a recent shift towards consumerism and patient empowerment has encouraged companies to reassess the role and structure of patient support programs.
This paper explores:
Please make sure you're subscribed to WARC to read the entire article or contact Bill Salokar if you don't have an access to WARC.
Be the first to receive the latest market research insights, tips from industry peers and exclusive content to help you influence decision behavior.
SKIM has named Maura Coracini as Managing Director, Latin America. Based in the São Paulo area.
Gain insights into what drives consumer decisions and how brands can strategically connect to boost engagement and accelerate growth.
Grey market threats are rising—discover how brands can protect customer loyalty with smarter strategies.
SKIM helps skincare brand TAKAMI optimize its subscription model through stakeholder interviews, collaborative innovation, and conjoint analysis.